New Drugs Chief: Vouchers Put FDA In 'Distasteful' Situation
This article was originally published in Scrip
Just as the House Oversight and Government Reform Committee decided it was time to look into whether the FDA's priority review vouchers (PRV) are being exploited, lawmakers on Capitol Hill also felt it was necessary to keep the specific portion of the program going for another six months that awards the "golden tickets" to firms that win approval of rare pediatric disease medicines – even though high-ranking US regulators would like to see it end.
You may also be interested in...
With new funding in hand, Moderna and its infectious disease venture Valera are going full-speed ahead with a Zika vaccine, taking an mRNA approach, which they said could be a more rapid strategy to try to stop the disease.
Allergan CEO Brent Saunders vows not to engage in price gouging and says his firm will limit cost increases to single-digit percentages, occurring only once per year. But it's unclear whether Saunders will stand as a lone wolf in the industry or if others will make similar pledges.
Hillary Clinton's plan to rein in high prices of older medicines, which includes creating a federal panel that has authority to impose fines, may grab headlines, but some analysts think it's unlikely to get very far in a divided Washington.